influenza
virus
segment
genom
show
great
antigen
divers
three
type
influenza
virusesa
b
conli
type
b
caus
widespread
outbreak
influenza
virus
classifi
subtyp
base
antigen
differ
two
surfac
glycoprotein
haemagglutinin
neuraminidas
haemagglutinin
subtyp
nine
neuraminidas
subtyp
identifi
influenza
virus
figur
virus
haemagglutinin
neuraminidas
subtyp
recov
aquat
bird
three
haemagglutinin
subtyp
two
neuraminidas
subtyp
establish
stabl
lineag
human
popul
sinc
one
subtyp
haemagglutinin
one
neuraminidas
recognis
influenza
b
virus
although
influenza
infect
selflimit
diseas
exert
huge
toll
suffer
econom
loss
despit
import
influenza
recent
littl
advanc
control
sinc
amantadin
licens
almost
year
ago
past
decad
evid
accru
protect
afford
inactiv
vaccin
safeti
efficaci
children
live
influenzaviru
vaccin
mani
new
develop
vaccin
technolog
moreov
work
viral
neuraminidas
led
licens
potent
select
antivir
drug
econom
decis
model
provid
justif
annual
vaccin
framework
use
neuraminidas
inhibitor
progress
also
made
develop
nearpati
test
influenza
may
assist
individu
diagnosi
recognit
widespread
viru
circul
optimis
clinic
manag
despit
advanc
occurr
avian
influenza
human
be
rapid
global
spread
sever
acut
respiratori
syndrom
remind
vulner
emerg
pandem
contrast
recent
case
infect
associ
high
mortal
typic
mild
selflimit
natur
human
infect
avian
influenza
show
gap
understand
molecular
correl
pathogen
underlin
need
continu
intern
research
pandem
influenza
improv
anim
human
surveil
new
approach
vaccin
increas
use
vaccin
antivir
drug
combat
annual
influenza
outbreak
essenti
reduc
global
toll
pandem
interpandem
influenza
review
intern
report
publish
english
decemb
data
nonsystemat
review
articl
identifi
search
medlin
embas
integr
scienc
citat
index
pubm
cochran
librari
electron
databas
relev
keyword
also
search
cite
refer
retriev
articl
review
articl
collect
mani
year
refer
textbook
influenza
use
knowledg
new
data
present
intern
scientif
meet
larg
number
articl
publish
everi
year
limit
number
citat
gave
emphasi
clinic
relev
issu
particularli
diseas
burden
emerg
new
subtyp
vaccin
antivir
diagnosi
gave
prioriti
randomis
control
trial
avail
larger
studi
articl
publish
highimpact
journal
wide
readership
systemat
review
econom
decis
model
prevent
treatment
influenza
commiss
health
technolog
assess
programm
behalf
nation
institut
clinic
excel
also
drew
knowledg
seem
appropri
fill
gap
publish
work
includ
sever
recent
pertin
articl
haemagglutinin
facilit
entri
viru
host
cell
attach
sialicacid
receptor
major
antigen
determin
type
b
virus
neutralis
antibodi
direct
crucial
compon
current
influenza
vaccin
import
function
neuraminidas
second
major
antigen
determin
catalys
cleavag
glycosid
linkag
sialic
acid
therebi
assist
releas
progeni
virion
infect
cell
accordingli
neuraminidas
becom
import
target
antivir
activ
ion
channel
influenza
block
antivir
drug
amantadin
regul
intern
ph
viru
crucial
earli
viral
replic
epidemiolog
behaviour
influenza
peopl
relat
two
type
antigen
variat
envelop
glycoproteinsantigen
drift
antigen
shift
antigen
drift
new
strain
viru
evolv
accumul
point
mutat
surfac
glycoprotein
new
strain
antigen
variant
relat
circul
preced
epidem
featur
enabl
viru
evad
immun
recognit
lead
repeat
outbreak
interpandem
year
antigen
shift
occur
emerg
new
potenti
pandem
influenza
viru
possess
novel
haemagglutinin
alon
novel
neuraminidas
new
viru
antigen
distinct
earlier
human
virus
could
arisen
mutat
figur
four
five
pandem
influenza
occur
centuri
interv
year
pandem
devast
million
death
estim
million
excess
death
repres
popul
occur
india
alon
howev
cumul
mortal
influenza
interven
year
gener
mani
time
greater
associ
pandem
although
influenza
b
virus
circul
virtual
everi
winter
temper
zone
northern
southern
hemispher
quantif
burden
influenza
consult
emergencydepart
examin
hospit
admiss
mortal
difficult
influenza
lack
pathognomon
featur
cocircul
respiratori
pathogen
caus
rang
nonspecif
complic
exacerb
chronic
cardiopulmonari
diseas
nevertheless
much
evid
subtyp
influenza
viru
caus
sever
ill
influenza
b
hospit
admiss
pneumonia
influenza
higher
number
excess
death
outbreak
sentinel
scheme
royal
colleg
gener
practition
network
england
report
increas
consult
rate
influenzalik
ill
respiratori
syndrom
strongli
associ
excess
mortal
england
wale
estim
peopl
die
epidem
estim
ten
time
number
death
certif
influenza
diseas
caus
mani
hidden
death
usa
influenzaassoci
excess
death
among
peopl
age
year
older
although
agerel
increas
death
influenz
ill
atrisk
lowrisk
group
death
hospit
admiss
occur
elderli
peopl
chronic
cardiopulmonari
disord
among
toddler
rate
influenzaassoci
hospit
admiss
usa
rang
per
popul
highrisk
condit
per
without
highrisk
condit
admiss
rate
highest
among
children
younger
year
similar
rate
found
among
peopl
age
year
older
among
children
hong
kong
china
number
excess
hospit
admiss
attribut
influenza
high
children
younger
month
per
respect
decreas
age
per
children
age
month
per
children
age
year
per
children
age
year
per
children
age
year
tropic
subtrop
influenza
occur
either
throughout
year
distinct
season
visibl
excess
mortal
twice
year
intens
activ
raini
season
consequ
morbid
mortal
influenza
probabl
greatli
underestim
region
summer
epidem
respiratori
ill
case
casemort
affect
madagascar
attribut
influenza
apanama
viru
loss
life
greatest
young
children
ascrib
malnutrit
poor
access
health
care
anoth
outbreak
attribut
influenza
viru
occur
novemb
decemb
district
bosobolo
democrat
republ
congo
casefat
rate
children
younger
year
peopl
rate
illustr
serious
outbreak
one
reason
improv
linkag
morbid
mortal
analysi
virolog
surveil
one
key
object
global
agenda
influenza
formul
southern
china
influenza
virus
circul
throughout
year
evid
origin
china
virus
caus
pandem
influenza
influenza
reemerg
influenza
recent
outbreak
avian
influenza
peopl
hong
kong
show
import
virolog
surveil
region
earli
detect
potenti
pandem
virus
also
evid
drift
variant
circul
china
year
caus
epidem
europ
north
america
region
thought
provid
appropri
ecolog
nich
emerg
new
influenza
virus
pandem
potenti
owe
proxim
dens
popul
peopl
pig
wild
domest
bird
therebi
facilit
genet
reassort
virus
differ
speci
figur
emerg
drift
variant
given
high
human
popul
densiti
yearround
viru
circul
observ
provid
impetu
improv
global
influenza
surveil
programm
china
provid
mani
vaccin
strain
recommend
past
decad
exampl
cite
indic
unpredict
influenzaviru
variat
great
capac
evolut
also
show
novelti
alon
insuffici
emerg
pandem
influenza
adapt
replic
human
be
abil
spread
person
person
suscept
popul
also
prerequisit
thu
emerg
new
influenzaviru
variant
human
popul
necessarili
herald
pandem
influenza
influenza
ahong
may
novemberdecemb
case
influenza
infect
identifi
peopl
hong
kong
outbreak
follow
seriou
outbreak
avian
influenza
chicken
farm
signal
possibl
incipi
pandem
human
influenza
isol
avian
origin
deriv
reassort
high
mortal
six
patient
die
acut
respiratori
distress
syndrom
multipl
organ
failur
previous
healthi
young
adult
suggest
unusu
aggress
clinic
cours
deterior
rapid
pneumonia
necessit
ventilatori
support
develop
within
day
ill
onset
strike
featur
sever
case
earli
onset
lymphopenia
high
concentr
serum
transaminas
fortun
secondari
infect
outbreak
ceas
chicken
hong
kong
million
slaughter
territori
poultri
stock
depopul
highli
pathogen
ahong
viru
reemerg
flock
may
februari
april
howev
human
case
influenza
identifi
februari
two
case
confirm
famili
hong
kong
resid
first
patient
boy
admit
hospit
hong
kong
recov
becam
unwel
travel
fujian
provinc
mainland
china
boy
father
die
hong
kong
hospit
sister
die
hospit
famili
china
caus
death
known
genet
analysi
two
isol
show
viru
gene
pure
avian
origin
differ
strain
infect
human
be
outbreak
hong
kong
heighten
surveil
adjoin
guandong
provinc
led
recoveri
nine
human
isol
viru
julyseptemb
march
influenza
virus
isol
two
children
hong
kong
ill
mild
selflimit
serolog
evid
infect
found
famili
member
healthcar
worker
close
contact
children
thu
virus
like
virus
seem
easili
transmit
person
person
three
lineag
viru
defin
prototyp
virus
avian
virus
isol
human
be
receptor
properti
similar
human
virusesi
bind
sialic
acid
linkag
contrast
bind
prefer
linkag
normal
found
avian
influenza
virus
hong
kong
antibodi
virus
found
blood
donor
suggest
human
infect
may
occur
local
surveil
pig
southern
china
shown
virus
cocircul
human
virus
porcin
virus
togeth
observ
indic
precursor
potenti
pandem
humanavian
reassort
place
februari
new
influenza
viru
isol
patient
influenzalik
ill
england
middl
east
uk
affect
mainli
young
children
virus
aros
reassort
segment
current
circul
influenza
subtyp
although
influenza
virus
identifi
previous
influenza
virus
isol
six
citi
china
viru
spread
limit
effect
season
attribut
good
preexist
immun
popul
four
peopl
contract
purul
conjunct
within
day
postmortem
examin
harbour
seal
die
outbreak
influenza
afowl
like
viru
cape
cod
usa
subsequ
recov
conjunctiva
investig
develop
conjunct
infect
anim
sneez
face
avian
viru
isol
uk
woman
conjunct
kept
duck
although
none
six
patient
respiratori
symptom
outbreak
highli
pathogen
avian
influenza
poultri
farm
netherland
began
end
februari
associ
fatal
respiratori
ill
one
human
case
april
person
die
previous
healthi
old
veterinari
surgeon
develop
sever
headach
renal
impair
interstiti
pneumonia
acut
respiratori
distress
visit
affect
poultri
farm
patient
present
conjunct
seven
respiratori
ill
transmiss
influenza
poultri
worker
famili
member
found
three
occas
viru
isol
obtain
human
be
accumul
signific
genet
chang
includ
case
humantohuman
transmiss
howev
viru
isol
person
die
aminoacid
substitut
suggest
role
pathogen
rapid
nearpati
test
influenza
aid
clinic
manag
use
exist
test
decis
whether
start
antivir
drug
treatment
limit
complex
low
sensit
tabl
howev
rapid
influenza
test
show
whether
viru
circul
specif
popul
local
may
becom
use
adjunct
surveil
programm
thu
treatment
antiinfluenza
drug
commonli
depend
patient
symptom
although
influenza
pathognomon
featur
diagnos
correctli
clinic
trial
twothird
adult
clinic
entri
criteria
met
cough
fever
temperatur
predict
symptom
influenza
fever
may
present
elderli
peopl
primari
care
patient
influenzalik
ill
diseas
outbreak
thu
optimum
implement
guidelin
antivir
treatment
depend
continu
communitybas
clinic
virolog
surveil
awar
gener
practition
influenza
circul
know
highli
pathogen
influenza
virus
deriv
studi
avian
influenza
virus
bird
situat
potenti
relev
diseas
human
be
mechan
pathogen
bird
may
oper
mammal
new
human
influenza
strain
may
come
ultim
avian
reservoir
tissu
tropism
capac
system
spread
import
determin
pathogen
bird
molecular
correl
pathogen
properti
resid
viral
haemagglutinin
well
studi
howev
mammal
factor
viral
haemagglutinin
involv
determin
pathogen
includ
viral
nonstructur
protein
neuraminidas
recoveri
nucleic
acid
pandem
viru
postmortem
tissu
preserv
human
remain
shown
highli
pathogen
viru
molecular
motif
haemagglutinin
associ
virul
avian
strain
use
revers
genet
techniqu
allow
direct
manipul
influenzaviru
gene
product
creation
new
recombin
virus
select
test
specif
mutat
engin
recombin
virus
mous
model
shown
greater
virul
obtain
specif
molecular
properti
haemagglutinin
fulli
explain
pathogen
balanc
viral
replic
host
immun
respons
determin
outcom
viral
infect
highli
virul
virus
remark
capac
resist
antivir
effect
host
cytokin
infect
human
macrophag
also
result
induct
high
cytokin
express
suggest
sever
outcom
infect
due
lack
inhibit
viral
replic
cytokin
excess
induct
cytokin
lead
tissu
damag
infect
host
key
genet
compon
determin
replic
highli
pathogen
viru
may
nonstructur
protein
viru
identifi
major
immun
modul
factor
contribut
pathogenesi
influenza
peopl
incomplet
understood
includ
understand
natur
tissu
restrict
proteas
differ
reactiv
innat
immun
system
differ
stage
life
vari
suscept
differ
human
popul
lead
differ
rang
diseas
certain
popul
exampl
encephalopathi
well
recognis
japan
less
popul
studi
mechan
virul
provid
simpli
elucid
pathogenesi
notabl
develop
altern
mean
attenu
influenza
virus
eg
delet
nonstructur
protein
matrix
protein
gene
make
safer
vaccin
strain
current
vaccin
produc
viru
grown
fertil
hen
egg
inactiv
either
formaldehyd
consist
whole
viru
detergenttr
split
product
purifi
haemagglutinin
neuraminidas
surfac
antigen
formul
three
viru
strain
current
recommend
countri
governmentfund
nation
immunis
programm
influenza
vaccin
avail
mani
other
million
world
popul
billion
vaccin
specif
vaccin
recommend
vari
involv
annual
vaccin
elderli
peopl
certain
chronic
medic
disord
recommend
found
proven
morbid
mortal
atrisk
group
consist
demonstr
vaccin
efficaci
militari
recruit
recognit
relat
antibodi
protect
proof
vaccin
antigen
wholeviru
vaccin
wide
avail
caus
advers
reaction
young
children
wherea
splitproduct
formul
contain
purifi
surfac
antigen
well
toler
extrem
safe
virtual
absenc
publish
report
suggest
hypersensit
reaction
rare
recent
randomis
control
trial
efficaci
effect
current
vaccin
studi
efficaci
effect
inactiv
influenza
vaccin
reveal
substanti
benefit
children
metaanalysi
doubleblind
singleblind
randomis
control
trial
estim
efficaci
vaccin
prevent
symptomat
laboratoryconfirm
influenza
tabl
benefit
includ
reduct
school
absente
otiti
media
asthma
exacerb
febril
respiratori
ill
unvaccin
household
contact
adult
work
age
metaanalysi
two
randomis
control
trial
split
influenza
vaccin
estim
efficaci
prevent
laboratoryconfirm
influenza
tabl
associ
benefit
includ
reduct
absente
consult
antibiot
use
use
overthecount
medic
frequenc
laboratoryconfirm
influenza
fell
vaccine
randomis
control
trial
tabl
prospect
cohort
studi
elderli
peopl
live
commun
mani
cohort
casecontrol
studi
shown
lower
rate
hospit
admiss
pneumonia
influenza
respiratori
disord
respiratori
disord
heart
failur
death
pneumonia
influenza
allcaus
mortal
vaccine
control
tabl
metaanalysi
report
publish
show
vaccin
reduc
number
case
influenzalik
ill
hospit
admiss
pneumonia
influenza
allcaus
mortal
prospect
observ
studi
nursinghom
resid
japan
show
reduct
laboratoryconfirm
influenz
ill
among
vaccine
vaccin
also
reduc
number
hospit
admiss
among
vaccin
failur
thu
appear
amelior
ill
sever
gross
colleagu
metaanalysi
cohort
studi
odd
ratio
develop
respiratori
ill
pneumonia
hospit
admiss
mortal
indic
substanti
protect
vaccin
elderli
patient
chronic
lung
diseas
reduc
hospit
admiss
pneumonia
influenza
allcaus
mortal
complic
death
exacerb
lung
diseas
pneumonia
heart
failur
angina
myocardi
infarct
influenza
vaccin
also
prevent
heart
failur
brain
infarct
recurr
myocardi
infarct
primari
cardiac
arrest
indic
import
benefit
patient
cardiovascular
diseas
vaccin
patient
diabet
mellitu
associ
estim
reduct
hospit
admiss
mostli
reason
diabet
control
thu
influenza
vaccin
protect
sever
potenti
fatal
event
explain
mani
hidden
death
accompani
epidem
staff
implic
sourc
influenza
sever
outbreak
nurs
home
accumul
influenza
vaccin
staff
care
elderli
peopl
longstay
facil
provid
benefit
resid
one
studi
show
substanti
herd
immun
protect
among
patient
expos
staff
high
vaccin
coverag
past
decad
mani
new
develop
vaccin
technolog
aid
vaccin
product
aim
improv
vaccin
immunogen
accept
subunit
influenza
vaccin
adjuv
emuls
squalen
water
parenter
use
licens
european
countri
uk
significantli
increas
haemagglutinationinhibit
antibodi
respons
interpandem
influenza
influenza
b
antigen
particularli
older
peopl
chronic
diseas
well
toler
despit
slightli
higher
rate
transient
mild
local
reaction
vaccin
virosom
consist
bilay
phospholipid
liposom
contain
viru
surfac
protein
embed
bilay
virosom
extens
evalu
variou
human
popul
typic
virosom
induc
higher
concentr
antibodi
vaccin
higher
rate
seroconvers
greater
proport
individu
protect
antibodi
titr
convent
inactiv
vaccin
virosom
influenza
vaccin
parenter
use
becam
avail
uk
season
cellcultur
vaccin
offer
potenti
abl
respond
quickli
epidem
pandem
time
year
avoid
risk
contamin
egg
could
affect
bioburden
endotoxin
content
vaccin
moreov
influenza
virus
grown
mammalian
cell
close
resembl
present
clinic
sampl
virus
isol
grown
egg
henc
offer
potenti
effect
vaccin
influenza
vaccin
prepar
madin
darbi
canin
kidney
mdck
african
green
monkey
vero
cell
substrat
licens
netherland
yet
avail
commerci
live
attenu
influenza
vaccin
intranas
deliveri
live
influenza
vaccin
offer
advantag
mimick
natur
infect
therebi
provid
broader
immunolog
respons
durabl
protect
inactiv
vaccin
strategi
use
live
influenza
vaccin
base
transfer
gene
code
cold
adapt
ca
temperatur
sensit
attenu
parent
viru
donor
use
russia
mani
year
approv
june
us
food
drug
administr
use
healthi
children
adolesc
age
year
healthi
adult
age
year
three
decad
clinic
evalu
vaccin
base
ca
replic
well
temperatur
found
nasopharynx
temperatur
lower
airway
young
children
recent
studi
us
ca
vaccin
show
high
protect
benefit
term
influenz
ill
otiti
media
second
year
studi
ca
vaccin
afford
high
degre
protect
variant
close
match
vaccin
antigen
studi
nursinghom
resid
suggest
combin
live
inactiv
influenza
vaccin
may
improv
protect
commun
immunostimul
complex
cagelik
structur
origin
form
complex
cholesterol
saponin
deriv
tree
quillaia
saponaria
vaccin
contain
defin
saponin
call
iscoprep
stimul
acceler
serum
antibodi
respons
human
be
compar
convent
inactiv
vaccin
improv
prolif
tcell
respons
cytotox
tcell
respons
although
nasal
deliv
influenza
vaccin
could
greatli
increas
vaccin
coverag
provid
mucos
immun
intranas
administr
convent
inactiv
influenza
vaccin
typic
unsuccess
anim
incorpor
mucos
adjuv
deriv
bacteria
necessari
improv
immunogen
sever
vaccin
administ
intranas
evalu
clinic
promis
result
intranas
spray
formul
contain
trival
subunit
influenza
vaccin
prepar
virosom
wildtyp
escherichia
coli
enterotoxin
licens
briefli
switzerland
although
met
immunogen
criteria
set
yearli
relicens
convent
influenza
vaccin
withdrawn
possibl
associ
bell
palsi
could
discount
variou
microparticl
investig
adjuv
deliveri
system
parenter
deliveri
influenzaviru
antigen
deliveri
mucos
site
includ
gut
subunit
influenza
vaccin
prepar
recombin
haemagglutinin
neuraminidas
protein
express
insect
cell
baculovirus
recombin
haemagglutinin
well
toler
young
adult
elderli
peopl
signific
doserespons
effect
haemagglutinin
vaccin
phase
viruschalleng
studi
baculovirusexpress
recombin
neuraminidas
healthi
volunt
promis
result
develop
reversegenet
techniqu
negativesens
rna
virus
allow
direct
manipul
influenzaviru
gene
product
creation
new
recombin
virus
approach
offer
enorm
potenti
prepar
interpandem
vaccin
nucleicacid
vaccin
dna
vaccin
present
promis
new
approach
vaccin
evok
full
rang
immun
respons
includ
antibodi
cytotox
helpertcel
respons
dna
vaccin
construct
encod
nucleoprotein
np
haemagglutinin
neuraminidas
matrix
protein
nonstructur
protein
influenza
viru
studi
extens
either
singli
combin
one
anoth
togeth
dna
encod
variou
cytokin
current
two
drug
class
avail
manag
influenza
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
seminar
lancet
vol
novemb
wwwthelancetcom
oseltamivir
rimantadin
caus
less
neurotox
amantadin
avail
part
world
discuss
amantadin
inhibit
membran
protein
ionchannel
activ
influenza
viru
effect
influenza
b
amantadin
three
import
limit
rang
activ
exclud
influenza
b
advers
sideeffect
includ
insomnia
lightheaded
hallucin
dizzi
headach
fall
particularli
troublesom
elderli
peopl
drug
resist
emerg
rapidli
treatment
genet
basi
resist
singl
nucleotid
chang
result
aminoacid
substitut
posit
membranespan
region
estim
amantadin
therapeut
effect
uncertain
owe
clinic
methodolog
heterogen
clinic
trial
pauciti
data
dose
small
number
trial
children
elderli
peopl
low
trialqual
score
treatment
healthi
adult
mg
daili
amantadin
cut
durat
fever
compar
placebo
day
data
use
current
licens
dose
uk
mg
daili
dose
amantadin
reduc
durat
fever
compar
placebo
day
metaanalysi
data
six
trial
involv
total
patient
effect
attain
statist
signific
highqual
evid
randomis
control
trial
effect
amantadin
mg
daili
treatment
influenza
atrisk
individu
ill
significantli
shorten
treatment
day
one
two
small
randomis
control
trial
children
randomis
trial
test
amantadin
outbreak
nurs
home
moreov
use
set
complic
toxic
treatment
failur
frequent
recoveri
drugresist
viru
amantadin
prophylaxi
popul
interpandem
outbreak
preclud
lack
highqual
evid
randomis
control
trial
licens
dose
high
increment
cost
per
qualityadjust
lifeyear
gain
secondgener
neuraminidas
inhibitor
potent
specif
inhibitor
wide
rang
influenza
viru
type
b
poor
oral
bioavail
deliv
inhal
zanamivir
licens
treatment
influenza
b
peopl
age
year
well
toler
number
type
sever
advers
event
healthi
adult
peopl
stabl
chronic
underli
medic
disord
differ
littl
placebo
main
safeti
concern
inhal
zanamivir
may
caus
bronchospasm
howev
respiratori
virus
includ
influenza
regularli
exacerb
asthma
chronic
obstruct
pulmonari
diseas
role
zanamivir
bronchospasm
unclear
zanamivir
administ
appar
safeti
two
studi
involv
patient
asthma
chronic
obstruct
pulmonari
diseas
difficulti
use
inhal
may
limit
use
zanamivir
one
studi
half
elderli
group
unabl
use
inhal
train
twothird
zanamivir
healthi
individu
age
year
atrisk
individu
includ
older
year
healthi
children
individu
healthi
individu
age
year
atrisk
individu
includ
older
year
healthi
children
individu
ittintentiontotreat
unabl
use
next
day
howev
three
studi
use
success
elderli
peopl
summari
result
draw
publish
unpublish
treatment
studi
zanamivir
shown
tabl
overal
symptom
allevi
sooner
zanamivir
placeboa
median
day
intentiontotreat
basi
day
influenzaposit
subgroup
zanamivir
median
time
return
normal
activ
day
shorter
treatment
group
intentiontotreat
influenzaposit
popul
pool
analysi
intentiontotreat
data
trial
includ
otherwis
healthi
atrisk
individu
antibiot
given
smaller
proport
patient
receiv
zanamivir
assign
placebo
tabl
similar
nonsignific
reduct
need
antibiot
highrisk
individu
pneumonia
seen
treatment
publish
unpublish
margin
analys
season
prophylaxi
zanamivir
mg
daili
mostli
unvaccin
healthi
adult
provid
estim
reduct
incid
laboratoryconfirm
clinic
influenza
compar
placebo
metaanalysi
two
randomis
control
trial
postexposur
prophylaxi
treatment
given
day
day
suggest
protect
symptomat
laboratoryconfirm
influenza
oseltamivir
thirdgener
neuraminidas
inhibitor
oral
activ
prodrug
oseltamivir
carboxyl
licens
treatment
influenza
b
peopl
age
year
older
prophylaxi
influenza
b
peopl
age
year
older
frequenc
nausea
higher
vomit
higher
placebo
gastrointestin
sideeffect
amelior
drug
taken
shortli
food
summari
result
draw
publish
unpublish
treatment
studi
oseltamivir
tabl
show
treatment
group
combin
symptom
allevi
sooner
oseltamivir
placebo
day
basi
intent
treat
day
influenzaposit
subgroup
similarli
normal
activ
resum
day
day
sooner
oseltamivir
intentiontotreat
influenzainfect
group
respect
treatment
oseltamivir
reduc
frequenc
otiti
media
antibiot
use
pneumonia
hospit
admiss
children
influenza
frequenc
otiti
media
placebo
oseltamivir
rate
antibiot
use
intentiontotreat
popul
one
studi
eight
placebo
one
treatment
pool
margin
analys
show
lower
rate
antibiot
use
lowerrespiratorytract
complic
healthi
highrisk
peopl
influenza
oseltamivir
placebo
lower
frequenc
pneumonia
influenzaposit
group
ten
studi
among
placebo
recipi
vs
oseltamivir
tabl
signific
reduct
occurr
hospit
admiss
influenzaposit
popul
ten
trial
vs
three
differ
strategi
prevent
laboratoryconfirm
symptomat
influenza
oseltamivir
investig
randomis
control
trial
metaanalysi
data
two
trial
season
prophylaxi
nonvaccin
healthi
adult
oseltamivir
mg
daili
gave
estim
protect
household
postexposur
prophylaxi
oseltamivir
mg
daili
day
gave
protect
similarli
season
prophylaxi
mostli
vaccin
elderli
peopl
receiv
residenti
care
oseltamivir
mg
daili
week
provid
protect
resist
neuraminidas
inhibitor
influenza
virus
low
suscept
neuraminidas
inhibitor
isol
vitro
vivo
resist
involv
either
mutat
activ
site
neuraminidas
alter
sensit
inhibit
mutat
haemagglutinin
mutat
haemagglutinin
confer
drug
resist
decreas
affin
protein
cellular
receptor
thu
enabl
viru
escap
infect
cell
without
need
viral
neuraminidas
date
virus
alter
suscept
neuraminidas
inhibitor
recov
patient
first
report
emerg
neuraminidaseinhibitor
resist
treatment
zanamivir
involv
recipi
bonemarrow
transplant
clinic
trial
oseltamivir
four
posttreat
isol
adult
adolesc
nine
children
low
neuraminidaseinhibitor
suscept
indic
virus
like
emerg
clinic
practic
three
resist
variant
neuraminidas
mutat
emerg
clinic
trial
show
low
infect
virul
anim
model
thu
relev
mutat
clinic
practic
remain
uncertain
intern
neuraminidas
suscept
network
establish
overse
global
surveil
neuraminidaseinhibitor
resist
uk
nation
institut
clinic
excel
nice
recent
issu
new
guidanc
interpandem
use
antivir
treatment
influenza
amantadin
recommend
neither
zanamivir
oseltamivir
recommend
treatment
influenza
children
adult
unless
risk
within
licens
indic
zanamivir
oseltamivir
recommend
treatment
atrisk
adult
oseltamivir
treatment
atrisk
children
present
influenzalik
ill
start
therapi
within
h
onset
symptom
known
influenza
b
circul
commun
nice
guidanc
use
antivir
drug
prevent
influenza
also
issu
late
oseltamivir
recommend
postexposur
prophylaxi
influenza
atrisk
peopl
age
year
older
begin
prophylaxi
within
h
live
residenti
care
establish
whether
vaccin
resid
staff
member
influenzalik
ill
effect
protect
vaccin
begin
prophylaxi
within
h
exposur
oseltamivir
recommend
postexposur
prophylaxi
healthi
peopl
age
year
season
prophylaxi
amantadin
recommend
either
postexposur
season
prophylaxi
guidanc
cover
circumst
pandem
hong
kong
chicken
flu
situat
rapid
global
spread
sever
acut
respiratori
syndrom
highlight
ill
prepar
introduc
prevent
measur
pandem
influenza
problem
encount
due
mainli
danger
work
chicken
viru
need
produc
safe
vaccin
strain
convent
technolog
unabl
produc
safe
product
vaccin
strain
howev
li
colleagu
abl
modifi
haemagglutinin
gene
ahong
viru
delet
seri
basic
aminoacid
residu
cleavag
site
associ
virul
use
revers
genet
rescu
modifi
haemagglutinin
gene
neuraminidas
gene
wildtyp
ahong
viru
ca
aann
viru
result
ca
viru
nonpathogen
anim
model
infect
grew
well
egg
protect
chicken
challeng
lethal
viru
could
suitabl
candid
vaccin
strain
experi
show
potenti
use
revers
genet
technolog
develop
live
inactiv
vaccin
pandem
interpandem
use
second
strategi
pandem
vaccin
develop
use
recombin
haemagglutinin
howev
disappoint
result
clinic
trial
baculovirusexpress
haemagglutinin
ahong
kong
viru
even
two
dose
question
role
strategi
alon
clinic
trial
convent
inactivatedsurfaceantigen
vaccin
produc
viru
show
extrem
poor
antibodi
respons
stimul
even
two
dose
wherea
subunit
vaccin
adjuv
much
immunogen
benefit
adjuv
use
popul
also
shown
wholeviru
vaccin
aluminium
salt
adjuv
thu
like
aluminium
salt
promis
increas
vaccin
coverag
respons
pandem
influenza
allow
scarc
antigen
use
effici
limit
inform
avail
convent
influenza
vaccin
seem
suffici
immunogen
pandem
situat
two
dose
conjunct
adjuv
may
need
differ
dose
strategi
variou
influenzaviru
subtyp
investig
robust
strategi
develop
vaccin
short
suppli
first
stage
pandem
antivir
drug
could
import
role
prevent
recent
prepar
draft
guidelin
use
vaccin
antivir
drug
pandem
emphasis
need
stockpil
drug
develop
plan
distribut
use
vaccin
gap
knowledg
antivir
drug
use
research
urgent
requir
ensur
effect
use
vaccin
drug
respons
emerg
pandem
kgn
receiv
fee
honoraria
roch
pharmaceut
wyeth
berna
biotech
speak
meet
influenza
research
support
chiron
vaccin
aventi
pasteur
wyeth
berna
biotech
solvay
berna
biotech
provid
avian
influenza
virus
free
charg
project
candid
pandem
vaccin
mz
receiv
honoraria
berna
biotech
speak
pharmaceuticalindustri
confer
influenza
support
attend
intern
workshop
viru
neutralis
sponsor
glaxosmithklin
health
protect
agenc
receiv
fund
chiron
vaccin
wyeth
vaccin
aventi
pasteur
roch
glaxosmithklin
carri
analyt
work
contractu
basi
mz
laboratori
jmw
conflict
interest
declar
relat
paper
none
sourc
fund
role
write
seminar
receiv
fund
relat
seminar
small
payment
lancet
learn
experi
use
error
reflect
medic
error
year
clinic
experi
disturb
note
error
came
mind
earli
part
career
sign
realli
becom
better
doctor
symptom
age
earli
error
influenti
subsequ
practic
current
error
recognis
made
known
sympathet
colleagu
first
hous
job
middleag
man
care
sever
month
infect
pleural
caviti
follow
plombag
oper
tuberculosi
year
previous
memor
sick
also
first
patient
give
present
day
month
later
casualti
offic
teach
hospit
intern
show
chest
radiograph
man
febril
ill
opaqu
hemithorax
lectur
intern
patient
infect
plombag
think
moment
stori
directli
relev
radiograph
shown
patient
die
cardiac
arrest
casualti
depart
autopsi
show
infect
plombag
site
death
untreat
septicaemia
year
qualifi
locum
physician
northern
part
canada
requir
coron
postmortem
middleag
man
found
dead
cabin
fortun
policeman
knew
overcam
anxieti
hour
later
doubt
man
dead
knew
neither
dissect
heart
coronari
vessel
decid
atheromat
death
natur
caus
probabl
myocardi
ischaemia
coron
court
present
conclus
case
close
receiv
pathologist
report
due
finish
locum
normal
heart
oncal
unit
one
patient
oner
task
particularli
staff
becom
numer
anonym
past
year
requir
oncal
unit
ten
consult
two
hospit
one
visit
call
telephon
middl
night
patient
cardiac
arrest
recognis
patient
name
told
arrest
team
want
advis
enthusiasm
resuscit
said
readili
resuscit
resort
extrem
measur
presum
cancer
patient
admit
care
one
oncolog
colleagu
visit
ward
next
morn
learnt
patient
die
young
woman
care
given
first
name
surnam
success
treat
ovarian
cancer
year
previous
diagnos
metastat
diseas
coupl
week
earlier
neutropen
first
chemotherapi
treatment
fatal
outcom
anticip
particularli
sinc
treat
cur
intent
